chemXplore tracks 87 projects in China, of which 42 are active.
Of the active ones, 29 new construction, 10 expansion and 3 revamp / retrofit.
23 active projects carry no start-up date yet. The dates themselves, per project, are for subscribers.
First Factor XIa inhibitor worldwide approved to lower recurrent ischemic stroke risk after non‑cardioembolic stroke or high‑risk TIA in adults.
Phase 3 G‑HOPE‑001 met dual endpoints in CLDN18.2‑positive advanced G/GEJA—median OS 10.2 vs 6.9 months and PFS 7.1 vs 3.1 months versus physician’s choice.
Group sales +6% (CER) in first nine months; Q3 +7% (CER)/+8% CHF. Pharmaceuticals drove growth, diagnostics up despite China pricing reforms. 2026 outlook confirmed.
Ethanol produced from steel mill waste gases is certified as Recycled Carbon Fuel, meeting RED III sustainability and GHG requirements and enabling access to EU/UK regulated fuel markets.
Pursues green transitions, technology independence, integrated retail‑energy services and early-stage investments to build diversified strategic growth poles.
Pushes integrated regional bases, oil‑to‑chemicals/specialty conversions, smart factories and capacity rationalisation to secure feedstocks and high‑end materials for advanced manufacturing.
Left Singapore on 18/10 bound for the Búzios pre-salt field; part of the 80-series of six platforms with nominal 225,000 bpd and 12 million m³ gas compression capacity; start expected next year.
Phase 3 ALKIVIA shows clinically meaningful, rapid improvements in IMNM and dermatomyositis, seen by Week 4 and sustained to Week 52; primary endpoint met (TIS +15.4).
Demand diversification, new industries and above‑ground constraints are driving cross‑border metals trade; Trafigura has deployed $7bn and invested in power, rail, storage and processing.
Late‑stage results show divarasib superiority in KRAS G12C NSCLC, giredestrant preserves quality of life while improving efficacy, and Tam‑Peli shows robust activity in nasopharyngeal carcinoma.
